Skye Bioscience (SKYE) Enterprise Value (2015 - 2026)

Skye Bioscience (SKYE) has reported Enterprise Value for 12 consecutive years, with -$7.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Enterprise Value rose 74.76% year-over-year to -$7.0 million in Q2 2026; TTM through Jun 2026 was -$7.0 million, a 74.76% increase from a year earlier, with the FY2025 full-year figure at -$22.6 million, up 60.65% from the prior year.
• Enterprise Value was -$7.0 million for Q2 2026 at Skye Bioscience, up from -$14.4 million in the prior quarter.
• Over five years, Enterprise Value peaked at $2.4 million in Q1 2022 and troughed at -$57.5 million in Q4 2024.
• A 5-year average of -$17.2 million and a median of -$10.7 million in 2026 frame the typical range for Enterprise Value.
• Across the five-year window, Enterprise Value jumped 643.42% in 2022 and plunged 1872.93% in 2024, its largest moves.
• Over 5 years, Enterprise Value stood at $1.1 million in 2022, then tumbled by 705.64% to -$6.7 million in 2023, then sank by 757.83% to -$57.5 million in 2024, then jumped by 60.65% to -$22.6 million in 2025, then soared by 68.89% to -$7.0 million in 2026.
• The last three Enterprise Value figures came in at -$7.0 million (Q2 2026), -$14.4 million (Q1 2026), and -$22.6 million (Q4 2025), per Business Quant data.